Interim phase 1 results show HPN328 is well tolerated and clinically active for neuroendocrine carcinomas – Dana-Farber News

Dana-Farber News recently shared a post on their X/Twitter page:

“ASCO GU24: Interim phase 1 results show HPN328, a T-cell engager, is well tolerated and clinically active for patients across a wide range of neuroendocrine carcinomas. Dana-Farber Cancer Institute’s Misha Beltran explains more here.”